ArticleOPEN ACCESS

Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV

AIDS
DOI: 10.1097/QAD.0000000000003017
76Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.
Get full text

Abstract

This study of SARS-CoV-2 mRNA vaccination in 14 persons with HIV (PWH) demonstrated uniformly high anti-SARS-CoV-2 receptor binding domain (RBD) antibody titres after two doses, despite varied titres after a single dose. The majority of vaccine reactions were mild and no adverse events occurred.

Cite

CITATION STYLE

APA

Ruddy, J. A., Boyarsky, B. J., Bailey, J. R., Karaba, A. H., Garonzik-Wang, J. M., Segev, D. L., … Werbel, W. A. (2021, November 15). Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV. AIDS. Lippincott Williams and Wilkins. https://doi.org/10.1097/QAD.0000000000003017

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free